Reports Q3 revenue $850.74M, consensus $810.55M. “Exact Sciences (EXAS) continues to advance our mission to prevent cancer and detect it earlier through a relentless focus on patients,” said Kevin Conroy, chairman and CEO. “Our third quarter results reflect the power of our patient-centric platform and our trusted brands, Cologuard and Oncotype DX. The momentum we are building is fueling growth, advancing innovative new tests like Cancerguard, and strengthening our financial performance.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- EXAS Upcoming Earnings Report: What to Expect?
- Exact Sciences’ Latest Study on Breast Cancer Recurrence Detection: A Potential Game Changer
- Exact Sciences’ MCED Test Study: A Potential Game-Changer in Early Cancer Detection
- EXAS, GH, PLTR, SOFI: Cathie Wood Invests $5.5M in Exact Sciences, Trims Stakes in Guardant, Palantir, SoFi, and Other Big Names
- Exact Sciences price target raised to $70 from $60 at Piper Sandler